1 recruiting, 1 terminated, 1 withdrawn. 2 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Recruiting 1, Withdrawn 1 |
| Phase 1 | 1 | Terminated 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow CIS: new trials by email Literature Review of CIS trials Research Report on CIS
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors SEphB4-HSA, Pembrolizumab, Gemcitabine - Muscle-Invasive Bladder Carcinoma, Metastatic Urothelial Carcinoma | Phase 2 / Phase 3 | Recruiting | Vasgene Therapeutics, Inc | 700 | 2025-03-15 | 2025-04-03 |
| Pneumoperitoneum Management With Low vs. Higher Pressure Questionnaires, Conventional Insufflation System (CIS), ConMed AirSeal Insufflation System (AIS) at Low Pressure - Malignant Neoplasms of Female Genital Organs | Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2018-07-01 | 2019-05-30 | |
| Study of PEGPH20 With Cisplatin (CIS) and Gemcitabine (GEM); PEGPH20 With Atezolizumab (ATEZO), CIS, and GEM; and CIS and GEM Alone in Participants With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma PEGPH20, CIS, GEM - Cholangiocarcinoma Non-resectable, Cholangiocarcinoma, Intrahepatic | Phase 1 | Terminated | Halozyme Therapeutics | 85 | 2017-10-02 | 2020-02-07 |
Carcinoma, Transitional Cell (1) · Cholangiocarcinoma (1)
Halozyme Therapeutics (1) · M.D. Anderson Cancer Center (1) · Vasgene Therapeutics, Inc (1)
United States (2) · South Korea (1) · Thailand (1)
Pedro T. Ramirez, MD (1) · Sarmad Sadeghi, MD (1)